Alunacedase alfa: meta-analysis of COVID-19 studies

All studies   Mortality   Ventilation   Serious outcomes   RCTs   RCT mortality   All outcomes  
Meta-analysis1 study · 178 patientsc19early.org

Alunacedase alfa for COVID-19

Serious outcome risk
Alunacedase alfa
Control
Outcome (studies)
Improvement
Relative risk · 95% CI
All studies (1)−31%
Mortality (1)−31%
Ventilation (1)23%
RCTs (1)−31%
Late (1)−31%
00.511.5+
← Alunacedase
alfa reduces riskIncreased
risk →
c19early.org
October 2026

Alunacedase alfa COVID-19 studies

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bundgaard (DB RCT)−31%1.31 · 0.51–3.38death9/887/90APN01-COVID-19
Late treatment−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Alunacedase alfa
reduces riskAlunacedase alfa
increases risk →
c19early.org
October 2026

Alunacedase alfa COVID-19 mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bundgaard (DB RCT)−31%1.31 · 0.51–3.389/887/90APN01-COVID-19
Late treatment−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Alunacedase alfa
reduces riskAlunacedase alfa
increases risk →
c19early.org
October 2026

Alunacedase alfa COVID-19 mechanical ventilation results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bundgaard (DB RCT)23%0.77 · 0.34–1.739/8812/90APN01-COVID-19
Late treatment23%0.77 · 0.34–1.739/8812/9023% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.53
All studies23%0.77 · 0.34–1.739/8812/9023% lower risk
Tau² = 0.00, I² = 0.0%, p = 0.5300.511.52+
Rotate screen for more detailsIncrease width for more details
← Alunacedase alfa
reduces riskAlunacedase alfa
increases risk →
c19early.org
October 2026

Alunacedase alfa COVID-19 serious outcomes

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bundgaard (DB RCT)−31%1.31 · 0.51–3.38death9/887/90APN01-COVID-19
Late treatment−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Alunacedase alfa
reduces riskAlunacedase alfa
increases risk →
c19early.org
October 2026

Alunacedase alfa COVID-19 Randomized Controlled Trials

StudyImprovementRR · 95% CIOutcomeTreatmentControlRelative Risk
Bundgaard (DB RCT)−31%1.31 · 0.51–3.38death9/887/90APN01-COVID-19
Late treatment−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Alunacedase alfa
reduces riskAlunacedase alfa
increases risk →
c19early.org
October 2026

Alunacedase alfa COVID-19 RCT mortality results

StudyImprovementRR · 95% CITreatmentControlRelative Risk
Bundgaard (DB RCT)−31%1.31 · 0.51–3.389/887/90APN01-COVID-19
Late treatment−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.58
All studies−31%1.31 · 0.51–3.389/887/9031% higher risk
Tau² = 0.00, I² = 0.0%, p = 0.5800.511.52+
Rotate screen for more detailsIncrease width for more details
← Alunacedase alfa
reduces riskAlunacedase alfa
increases risk →